Technical Analysis for CORI - Corium International, Inc.

Grade Last Price % Change Price Change
grade A 12.68 0.24% 0.03
CORI closed up 0.24 percent on Monday, November 26, 2018, on 3.39 times normal volume.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Up Up Flat
See historical CORI trend table...

Date Alert Name Type % Chg
Oct 12 Crossed Above 200 DMA Bullish -0.16%
Oct 12 Crossed Above 20 DMA Bullish -0.16%
Oct 12 Crossed Above 50 DMA Bullish -0.16%
Oct 12 MACD Bullish Centerline Cross Bullish -0.16%
Oct 12 MACD Bullish Signal Line Cross Bullish -0.16%
Oct 12 Stochastic Buy Signal Bullish -0.16%
Oct 12 Pocket Pivot Bullish Swing Setup -0.16%
Oct 12 Volume Surge Other -0.16%
Oct 12 Narrow Range Bar Range Contraction -0.16%
Oct 11 Volume Surge Other 52.59%

Older signals for CORI ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Corium International, Inc., a biopharmaceutical company, focuses on the research, development, manufacture, and commercialization of specialty pharmaceutical products. Its products include Clonidine Transdermal Delivery System (TDS), a treatment for hypertension; Fentanyl TDS, a treatment for management of chronic pain, including cancer-related pain; Crest Whitestrips, a series of four products under the Advanced Vivid, Professional Effects, One Hour Express, and Flex-Fit brands for oral care. The company is also developing AG200-15, a combination hormonal contraceptive patch in Phase III clinical trials that delivers ethinyl estradiol and levonorgestrel hormones; MicroCor hPTH(1-34), a transdermal system, which has completed Phase I clinical trials for the treatment of severe osteoporosis; and Corplex Tamsulosin that has completed Phase I clinical trials for the treatment of benign prostatic hyperplasia. In addition, its products that have completed development, scale-up, and clinical activities include motion sickness patch for the prevention of nausea and vomiting associated with motion sickness; and urology patch for treatment of a urologic condition. Further, the company is developing Donepezil and Memantine transdermal patches for the treatment of Alzheimer's disease; and Ropinerole and Pramipexole therapies for the treatment of Parkinson's disease. Corium International, Inc. has collaboration agreements with The Procter & Gamble Company, Teva Pharmaceuticals USA, Inc., Par Pharmaceutical, Inc., and Agile Therapeutics, Inc. The company was incorporated in 1995 and is headquartered in Menlo Park, California.
Is CORI a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 4 bullish, 0 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Recent News
Date Title
Nov 12 Health Care Digest: A big Berkeley bio incubator, Apple's clinical trial help and more
Nov 8 Bragar Eagel & Squire, P.C. Reminds Investors that it is Investigating the Boards of Directors of Corium, Hamilton, and Penn Virginia on Behalf of Stockholders and Encourages Investors to Contact the Firm
Nov 6 URGENT: Monteverde & Associates PC Continues Investigation of XOXO, CORI, PLRM, P, EGL, EGN, NXEO, and SIR
Nov 1 Lifshitz & Miller LLP Announces Investigation of Corium International, Inc., Dragon Victory International Limited, Honeywell International Inc., Hortonworks, Inc., Idaho Independent Bank, L3 Technologies, Inc., MBT Financial Corp., Nevro Corp., and Orm...
Nov 1 MERGER ALERT – CORI and ESIO: Levi & Korsinsky, LLP Reminds Investors of Investigations Concerning the Sale of these Companies
Nov 1 Bragar Eagel & Squire, P.C. Reminds Investors that it is Investigating the Boards of Directors of Corium, L3, SendGrid, and InfraREIT on Behalf of Stockholders and Encourages Investors to Contact the Firm
Oct 31 CryptoZink to Present at Malta Blockchain Summit
Oct 31 Wolf Haldenstein Adler Freeman & Herz LLP Announces that it has Filed a Class Action Complaint in the United States District Court for the Northern District of California on Behalf of holders of Corium International, Inc.
Oct 30 INVESTOR ALERT: CORIUM TENDER OFFER SET TO EXPIRE ON NOVEMBER 26, 2018; WeissLaw LLP Reminds CORI Shareholders of Its Investigation Concerning the Acquisition of Corium International, Inc.
Oct 26 READ NOW: Monteverde & Associates PC is Investigating the Tender Offer of Corium International, Inc. Set to Expire on November 26, 2018 - CORI
See more CORI news...
Indicator Value
52 Week High 13.93
52 Week Low 7.17
Average Volume 1,202,799
200-Day Moving Average 10.0905
50-Day Moving Average 11.2602
20-Day Moving Average 12.631
10-Day Moving Average 12.654
Average True Range 0.1268
ADX 49.72
+DI 42.5788
-DI 11.4133
Chandelier Exit (Long, 3 ATRs ) 12.3646
Chandelier Exit (Short, 3 ATRs ) 12.9204
Upper Bollinger Band 12.6961
Lower Bollinger Band 12.5659
Percent B (%b) 0.88
BandWidth 1.030797
MACD Line 0.3304
MACD Signal Line 0.4315
MACD Histogram -0.1011
Fundamentals Value
Market Cap 453.2 Million
Num Shares 35.7 Million
EPS -1.72
Price-to-Earnings (P/E) Ratio -7.37
Price-to-Sales 10.96
Price-to-Book 12.08
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 12.82
Resistance 3 (R3) 12.83 12.79 12.80
Resistance 2 (R2) 12.79 12.75 12.78 12.79
Resistance 1 (R1) 12.73 12.73 12.76 12.73 12.78
Pivot Point 12.69 12.69 12.71 12.69 12.69
Support 1 (S1) 12.64 12.66 12.67 12.63 12.58
Support 2 (S2) 12.60 12.63 12.59 12.57
Support 3 (S3) 12.54 12.60 12.56
Support 4 (S4) 12.54